Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hennessy

Showing results (191-200 of 249) with videos related to

Pageof 25
Sort By:
Journal of the National Cancer Institute|July 6, 2016
RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast CancerSinead Toomey, Alex J Eustace, Laura B Pritzker, et al.
British Journal of Cancer|July 28, 2023
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapyNicola Gaynor, Alfonso Blanco, Stephen F Madden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2011
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancerAna M Gonzalez-Angulo, Kirsten M Timms, Shuying Liu, et al.
BMC Cancer|January 15, 2026
Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancerDavid Easty, Ray McDermott, Adrian G Murphy, et al.
Molecular Oncology|June 6, 2015
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patientsShannon N Westin, Zhenlin Ju, Russell R Broaddus, et al.
Oncotarget|October 25, 2016
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancerSinead Toomey, Stephen F Madden, Simon J Furney, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 18, 2024
Quality-of-Life Analysis of a Phase II Randomised Controlled Trial Comparing Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy in Locally Advanced Rectal CancerR L Geary, C Gillham, G McVey, et al.
BMC Cancer|August 7, 2025
Neoadjuvant chemoradiation in older Irish adult patients with oesophageal cancer: a retrospective institutional review of clinical outcomes and hematological toxicityRonan Andrew McLaughlin, David McMahon, Christopher Cluxton, et al.
Thorax|October 24, 2020
Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19)Daniel J Ryan, Sinead Toomey, Stephen F Madden, et al.
Molecular Cancer Therapeutics|February 4, 2010
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line setEun Sung Park, Rosalia Rabinovsky, Mark Carey, et al.
Pageof 25

Showing results (191-200 of 249) with videos related to

Sort By:
Pageof 25
Journal of the National Cancer Institute|July 6, 2016
RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast CancerSinead Toomey, Alex J Eustace, Laura B Pritzker, et al.
British Journal of Cancer|July 28, 2023
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapyNicola Gaynor, Alfonso Blanco, Stephen F Madden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2011
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancerAna M Gonzalez-Angulo, Kirsten M Timms, Shuying Liu, et al.
BMC Cancer|January 15, 2026
Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancerDavid Easty, Ray McDermott, Adrian G Murphy, et al.
Molecular Oncology|June 6, 2015
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patientsShannon N Westin, Zhenlin Ju, Russell R Broaddus, et al.
Oncotarget|October 25, 2016
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancerSinead Toomey, Stephen F Madden, Simon J Furney, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 18, 2024
Quality-of-Life Analysis of a Phase II Randomised Controlled Trial Comparing Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy in Locally Advanced Rectal CancerR L Geary, C Gillham, G McVey, et al.
BMC Cancer|August 7, 2025
Neoadjuvant chemoradiation in older Irish adult patients with oesophageal cancer: a retrospective institutional review of clinical outcomes and hematological toxicityRonan Andrew McLaughlin, David McMahon, Christopher Cluxton, et al.
Thorax|October 24, 2020
Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19)Daniel J Ryan, Sinead Toomey, Stephen F Madden, et al.
Molecular Cancer Therapeutics|February 4, 2010
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line setEun Sung Park, Rosalia Rabinovsky, Mark Carey, et al.
Pageof 25